Biosensors’ total income decreases 6.06 percent to of $77.5 million in Q3 FY15 Biosensors International Group, Ltd. , a developer, producer and internet marketer of innovative medical products, today announced financial outcomes for the third one fourth of its Fiscal Calendar year 2015 and nine a few months ended 31 December 2014 . Third One fourth Highlights and Recent Advancements: Management made significant improvement in optimizing the organization's cost framework. In Q3 FY15, operating income rose 4 percent year-over-12 months and 53 percent quarter-over-one fourth, reversing many quarters of stagnation. Total revenue was $77.5 million, in comparison to $82.5 million in the 3rd quarter of Fiscal Year 2014 , due mainly to unfavorable forex impact.The experts compared the survival of 345 of the sufferers who had only surgery with 271 who had been then treated with 5-fluorouracil -centered chemotherapy agents and contemporary types of radiation. Individuals receiving the combined chemotherapy and radiation experienced a better median survival in comparison to patients who didn’t . Two-12 months survival also improved , as did five-year survival . In the July 20 issue of the Journal of Clinical Oncology Results will be published. ‘The take-house message of the study is that individuals who received combined chemotherapy and radiation seemed to have better survival than sufferers who have surgery by itself, suggesting that it is safe and beneficial whether it’s done cautiously and properly,’ says Herman, associate professor in the Department of Radiation Molecular and Oncology Radiation Sciences.